Advertisement
Advertisement

CTNM

CTNM logo

Contineum Therapeutics, Inc. Class A Common Stock

14.30
USD
Sponsored
-0.30
-2.03%
Jan 30, 16:00 UTC -5
Closed
exchange

After-Market

14.30

0.00
+0.01%

CTNM Earnings Reports

Positive Surprise Ratio

CTNM beat 2 of 7 last estimates.

29%

Next Report

Date of Next Report
Mar 04, 2026
Estimate for Q4 25 (Revenue/ EPS)
$5.10M
/
-$0.44
Implied change from Q3 25 (Revenue/ EPS)
--
/
-2.22%
Implied change from Q4 24 (Revenue/ EPS)
--
/
-21.43%

Contineum Therapeutics, Inc. Class A Common Stock earnings per share and revenue

On Oct 30, 2025, CTNM reported earnings of -0.45 USD per share (EPS) for Q3 25, beating the estimate of -0.49 USD, resulting in a 8.80% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +4.46% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analysts forecast an EPS of -0.44 USD, with revenue projected to reach 5.10 million USD, implying an decrease of -2.22% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
For Q3 2025, Contineum Therapeutics, Inc. Class A Common Stock reported EPS of -$0.45, beating estimates by 8.8%, and revenue of $0.00, 0% as expectations.
The stock price moved up 4.46%, changed from $10.54 before the earnings release to $11.01 the day after.
The next earning report is scheduled for Mar 04, 2026.
Based on 10 analysts, Contineum Therapeutics, Inc. Class A Common Stock is expected to report EPS of -$0.44 and revenue of $5.10M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement